Publikationen in Zusammenarbeit mit Forschern von GlaxoSmithKline (United Kingdom) (4)

2003

  1. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults

    Journal of Antimicrobial Chemotherapy, Vol. 52, Núm. 5, pp. 826-836

2000

  1. Streptococcus pneumoniae in community-acquired respiratory tract infections in Spain: The impact of serotype and geographical, seasonal and clinical factors on its susceptibility to the most commonly prescribed antibiotics

    Journal of Antimicrobial Chemotherapy, Vol. 46, Núm. 4, pp. 557-564

1999

  1. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: Results of a 1-year (1996-1997) multicenter surveillance study

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 2, pp. 357-359

  2. Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study

    Antimicrobial Agents and Chemotherapy, Vol. 43, Núm. 1, pp. 178-180